Caileigh Dougherty
Geen lopende functies
Profiel
Caileigh Dougherty worked as Director-Investor Relations at Athenex, Inc. and as Head-Investor Relations at Intercept Pharmaceuticals, Inc.
Eerdere bekende functies van Caileigh Dougherty
| Bedrijven | Functie | Einde |
|---|---|---|
| ATHENEXPAR | Public Communications Contact | 01-09-2022 |
| INTERCEPT PHARMACEUTICALS, INC. | Public Communications Contact | 01-08-2021 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Athenex, Inc.
 Athenex, Inc. Pharmaceuticals: MajorHealth Technology Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY. | Health Technology |
